IQVIA - The invisible engine behind every new drug

5-year stock timeline

Key Points

From recommendation (January 3, 2026)

• Market leader for clinical trials and healthcare data with 32.4 billion USD Order backlog
• Book-to-bill ratio of 1.15x signals continued strong demand
• Strategic partnership with AWS for AI-powered healthcare platform
• ROE of 19.4% well above the life sciences average of 12
• Share buybacks of 1.03 billion USD in nine months 2025

Investment Thesis

From recommendation (January 3, 2026)

IQVIA is the backbone of modern drug development - a position the company has built up over decades through the combination of a unique database, operational excellence and deep customer relationships. Without IQVIA, pharmaceutical companies would simply not be able to get new drugs through the complex regulatory processes. The recent AWS partnership and the settlement of the legal dispute with Veeva Systems create additional growth prospects, while the order backlog of USD for multi-year sales visibility. With a PEG of 0.96 and expected EPS growth rates of 6.9% (2025) and 8.4% (2026), the share offers a valuation below the growth momentum - a rare setup for an infrastructure champion in the healthcare sector.

Key risks and downside factors

IQVIA operates as a major global provider across three interconnected domains: clinical research services, contract research organization capabilities, and healthcare data with analytics. The company faces competition on multiple fronts—large CROs compete directly for trial work, while specialized vendors in data, analytics, and life-sciences software pursue the same real-world evidence and commercial insights that IQVIA targets. Pressure intensifies from integrated CROs offering comprehensive trial solutions end-to-end, and from cloud platforms, analytics firms, tech companies, and hyperscalers introducing alternative approaches through decentralized trials, AI capabilities, and new data sources. The company's growth and profitability face headwinds from regulatory constraints, data-privacy requirements, concentration among key clients, and persistent margin compression.

• Tighter data-privacy regulations—including cross-border transfer limits and restrictions on patient-level datasets—could constrain access to real-world data and raise compliance expenses [regulatory and privacy risk].
• Competitive displacement and technology risk stem from potential client loss or margin compression driven by large CRO integrations, specialized niche CROs, cloud and hyperscaler analytics platforms, or decentralized trial specialists offering services or data advantages that undercut IQVIA's positioning.
• Customer concentration and contract risk present material exposure through reliance on major pharma and biotech clients, particularly where large multi-year contracts dominate revenue streams. Should key sponsors reduce spending or shift services in-house, the revenue impact would be substantial [1].
• Operational and execution risk stems from the complexity inherent in running large global trials, integrating acquisitions, and navigating persistent shortages in clinical staff and data scientists. These pressures can inflate costs, push timelines backward, and ultimately compress profitability.

Competitive landscape

IQVIA operates as a major global provider of clinical research services, real-world data, and healthcare analytics across the biopharma and healthcare sectors. The competitive landscape fragments across service lines, with large contract research organizations like ICON, Labcorp Drug Development, Syneos, and PPD competing directly on CRO services, while specialized vendors in data, analytics, and software—Veeva, Clarivate, Definitive Healthcare among them—compete in their respective domains. The company faces material risks around executing and integrating large acquisitions and technology platforms. Pricing pressure persists in both CRO and data services markets. Regulatory and privacy constraints on patient-level data create operational friction. Customer concentration among large biopharma firms and sensitivity to macroeconomic cycles and clinical trial funding flows represent structural vulnerabilities [1].

Catalysts

From recommendation (January 3, 2026)

• Integration of the AWS partnership in commercial offerings and AI platform
• Veeva cooperation could accelerate software and data integration
• EPS forecasts for 2026 at USD 12.94 (+8.8% compared to 2025)
• Sustained high RFP volume (+20% YoY) signals industry recovery
• Further share buybacks with solid free cash flow generation

Analysis

From recommendation (January 3, 2026)

Performance Figures of IQVIA Holdings Inc

in USD

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

From recommendation (January 3, 2026)

Key Metrics

From recommendation (January 3, 2026)

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

No dividend data available.

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in USD

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.